Prognostic Value of Biomarkers in COVID-19: Associations with Disease Severity, Viral Variants, and Comorbidities—A Retrospective Observational Single-Center Cohort Study
Authors:
- Zoran BarušićZBZoran Barušić
- Kristian BodulićKBKristian Bodulić
- Sanja ZemberSZSanja Zember
- Renata LaškajRLRenata Laškaj
- Rok ČivljakRok Čivljak
- Ivan PuljizIPIvan Puljiz
- Ivan-Christian KuroltIvan-Christian Kurolt
- Željka Mačak ŠafrankoŽŠŽeljka Mačak Šafranko
- Lidija Cvetko KrajinovićLidija Cvetko Krajinović
- Petra Svoboda KarićPKPetra Svoboda Karić
- Alemka MarkotićAlemka Markotić
Open Access
Abstract
Coronavirus disease (COVID-19) exhibits a wide spectrum of clinical severity and has been associated with specific biomarkers linked to disease progression and outcomes. This retrospective study analyzed sera from 1222 adult COVID-19 patients hospitalized at the University Hospital for Infectious Diseases in Croatia. We examined the association between several laboratory biomarker levels measured at patient admission and disease severity, fatal outcomes, viral variants and clinical parameters. Deceased patients and surviving patients with severe COVID-19 exhibited significantly elevated levels of several biomarkers on admission, including hs-troponin T, N-terminal pro-brain natriuretic peptide, creatine kinase, C-reactive protein, procalcitonin, interleukin-6, lactate dehydrogenase, lactate, urea and creatinine. Random forest models identified lymphocyte percentage, D-dimers, and hs-troponin T as the most important biomarkers for fatal outcome prediction, achieving 84.1% accuracy. Patients infected with the Delta SARS-CoV-2 variant exhibited significantly higher levels of proinflammatory, cardiac and renal biomarkers. Vaccination correlated with reduced proinflammatory parameters and higher lymphocyte proportions. Hypertension, chronic renal disease and diabetes were associated with increased cardiac, renal and metabolic biomarker levels, respectively. These findings highlight the association of several laboratory biomarkers with COVID-19 severity, viral variants, vaccination status and comorbidities, potentially offering prognostic insights into COVID-19 outcomes.Keywords
Funding Information
- European Structural and Investment Funds (KK.01.2.2.03.0006, KK.01.1.1.01.0006)
- Scientific Centre of Excellence for Virus Immunology and Vaccines (KK.01.2.2.03.0006, KK.01.1.1.01.0006)
This publication has 36 references indexed in Scilit:
- An explainable machine learning model for COVID-19 severity prognosis at hospital admissionInformatics in Medicine Unlocked, 2024
- Vaccination against COVID-19 reduced the mortality risk of COVID-positive hip fracture patients to baseline levels: the nationwide data-linked IMPACT Protect studyOsteoporosis International, 2023
- The Relationship of COVID-19 Vaccination with Mortality Among 86,732 Hospitalized Patients: Subpopulations, Patient Factors, and Changes over TimeJournal of General Internal Medicine, 2023
- Impact of vaccination on the presence and severity of symptoms in hospitalized patients with an infection of the Omicron variant (B.1.1.529) of the SARS-CoV-2 (subvariant BA.1)Clinical Microbiology and Infection, 2022
- Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology featuresMolecular and Cellular Biochemistry, 2022
- Circulating ACE2 activity predicts mortality and disease severity in hospitalized COVID-19 patientsInternational Journal of Infectious Diseases, 2021
- A comprehensive review of vascular complications in COVID-19Journal of Thrombosis and Thrombolysis, 2021
- Characterization of NT‐proBNP in a large cohort of COVID‐19 patientsEuropean Journal of Heart Failure, 2021
- Covid‐19 and kidney injury: Pathophysiology and molecular mechanismsReviews in Medical Virology, 2020
- Predictors of COVID‐19 severity: A literature reviewReviews in Medical Virology, 2020